{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:24Z","timestamp":1787003604351,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast growth factor-21 (FGF-21) and Visfatin are associated with obesity. However; reviewing the literature; no studies were found to assess their role as potential markers for the metabolic disorders related to obesity in children. Assess the relations between serum FGF-21 and Visfatin with obesity and its metabolic disorders, and their use as potential predictors for metabolic risk factors in a sample of Egyptian obese children. This cross-sectional study included 111 Egyptian children (45 males and 66 females); aged 6\u201310\u00a0years to avoid the effect of puberty (prepubertal). The exclusion criteria (by full History taking and clinical examination) were the presence of any sign of puberty according to Tanner stage, the presence of identified causes of obesity (genetic syndromes, chromosomal or endocrinal disorders), chronic diseases (cardiovascular, gastrointestinal, and respiratory), or drug use like steroids; that would interfere with the type of obesity and affect the normal growth of the children. Also, any child with a BMI between 85 and 95th percentiles (overweight) was excluded from the study. All participating obese children were suffering from exogenous simple obesity. They were classified according to their body mass index (BMI) percentiles into 72 obese (BMI\u2009\u2265\u200995th), and 39 control non-obese ones (BMI\u2009&gt;\u200915th to\u2009&lt;\u200985th), based on the Egyptian Growth Charts for children and adolescents. Ethical approvals were granted from both the Ethics Committee of the \u201cNational Research Centre\u201d and the \u201cFaculty of Postgraduate Childhood Studies\u201d (Approval No. 17\/125). Also, informed written consent was taken from either of the parents and assent from the participating children. They were subjected to blood pressure assessment, anthropometric measurements (weight [Wt], height [Ht], BMI, waist [WC], and hip [HC] circumferences), and laboratory evaluation (Visfatin, FGF-21, LDL, HDL, TG, cholesterol, fasting glucose, insulin, and calculation of HOMA-IR). Mann\u2013Whitney test and Spearman\u2019s correlation test were applied. Obese children had significantly higher values than control ones regarding all the studied clinical (SBP, DBP), anthropometric parameters (Wt, Ht, BMI, WC, and HC), FBG, Insulin, HOMA-IR, Visfatin, and FGF-21, and had significantly lower values regarding HDL and Cholesterol. Among obese children, both FGF-21 and Visfatin had significant negative correlations with BMI and HC. At the same time, serum FGF-21 had a highly significant positive correlation with HDL. Visfatin and FGF-21 had highly significant positive correlations with each other. In the control group, both serum Visfatin or FGF-21 had insignificant correlations with each other and with all the studied clinical and anthropometric parameters. FGF-21 and Visfatin are related to the obesity markers, but they cannot be used as potential predictors for metabolic disturbance in obese prepubertal children; both had insignificant correlations with the metabolic risk factors.<\/jats:p>","DOI":"10.1038\/s41598-024-51394-z","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T05:02:16Z","timestamp":1705035736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fibroblast growth factor-21 and Visfatin as potential predictors for metabolic risk factors in obese children"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1416-0633","authenticated-orcid":false,"given":"Sahar A.","family":"El-Masry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-5528","authenticated-orcid":false,"given":"Maisa Nasr","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-0024","authenticated-orcid":false,"given":"Nayera E.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9368-2570","authenticated-orcid":false,"given":"Muhammad Al-Tohamy","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-7466","authenticated-orcid":false,"given":"Lamis H","family":"Mekkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-5512","authenticated-orcid":false,"given":"Galal Ismail","family":"Elashry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-5803","authenticated-orcid":false,"given":"Safa N.","family":"Abd El-Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"1","key":"51394_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4274\/jcrpe.3682","volume":"9","author":"T K\u00fcme","year":"2017","unstructured":"K\u00fcme, T. et al. The relationship between serum zonulin level and clinical and laboratory parameters of childhood obesity. J. Clin. Res. Pediatr. Endocrinol. 9(1), 31 (2017).","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"issue":"1","key":"51394_CR2","first-page":"9","volume":"66","author":"NE Hassan","year":"2018","unstructured":"Hassan, N. E. et al. Relationship between breast feeding duration and risk of overweight\/obesity among Egyptian children. Egypt. Pediatr. Assoc. Gaz. 66(1), 9\u201314 (2018).","journal-title":"Egypt. Pediatr. Assoc. Gaz."},{"issue":"1","key":"51394_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00431-020-03777-3","volume":"180","author":"G Tuli","year":"2021","unstructured":"Tuli, G. et al. Distribution of plasma copeptin levels and influence of obesity in children and adolescents. Eur. J. Pediatr. 180(1), 119\u2013126 (2021).","journal-title":"Eur. J. Pediatr."},{"issue":"10","key":"51394_CR4","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.3390\/ijms21103570","volume":"21","author":"K Zorena","year":"2020","unstructured":"Zorena, K., Jachimowicz-Duda, O., \u015al\u0119zak, D., Robakowska, M. & Mrugacz, M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int. J. Mol. Sci. 21(10), 3570 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"51394_CR5","first-page":"116","volume":"18","author":"B Kumari","year":"2018","unstructured":"Kumari, B. & Yadav, U. Adipokine Visfatin\u2019s role in pathogenesis of diabesity and related metabolic derangements. Curr. Mol. Med. 18(2), 116\u2013125 (2018).","journal-title":"Curr. Mol. Med."},{"issue":"10","key":"51394_CR6","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/ijo.2010.280","volume":"35","author":"G\u00c1 Martos-Moreno","year":"2011","unstructured":"Martos-Moreno, G. \u00c1. et al. Serum Visfatin and vaspin levels in prepubertal children: Effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int. J. Obes. (Lond.) 35(10), 1355\u20131362 (2011).","journal-title":"Int. J. Obes. (Lond.)"},{"issue":"1","key":"51394_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12902-019-0452-6","volume":"19","author":"C Yin","year":"2019","unstructured":"Yin, C., Hu, W., Wang, M. & Xiao, Y. The role of the adipocytokines vaspin and Visfatin in vascular endothelial function and insulin resistance in obese children. BMC Endocr. Disord. 19(1), 127 (2019).","journal-title":"BMC Endocr. Disord."},{"issue":"11","key":"51394_CR8","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng, L., Lam, K. & Xu, A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nat. Rev. Endocrinol. 16(11), 654\u2013667 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"51394_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3389\/fphar.2020.01279","volume":"11","author":"G Wu","year":"2020","unstructured":"Wu, G. et al. Hypoxia-induced adipose lipolysis requires fibroblast growth factor 21. Front. Pharmacol. 11, 1279 (2020).","journal-title":"Front. Pharmacol."},{"issue":"3","key":"51394_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7570\/jomes.2017.26.3.204","volume":"26","author":"J Baek","year":"2017","unstructured":"Baek, J., Nam, H. K., Rhie, Y. J. & Lee, K. H. Serum FGF21 levels in obese Korean children and adolescents. J. Obes. Metab. Syndr. 26(3), 204\u2013209 (2017).","journal-title":"J. Obes. Metab. Syndr."},{"issue":"6","key":"51394_CR11","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1210\/jc.2012-1221","volume":"97","author":"T Reinehr","year":"2012","unstructured":"Reinehr, T., Woelfle, J., Wunsch, R. & Roth, C. L. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: A longitudinal analysis. J. Clin. Endocrinol. Metab. 97(6), 2143\u20132150 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"51394_CR12","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang, X. et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(5), 1246\u20131253 (2008).","journal-title":"Diabetes"},{"key":"51394_CR13","volume-title":"Crecere Nel Mondo","author":"I Ghalli","year":"2008","unstructured":"Ghalli, I. et al. Egyptian growth curves for infants, children and adolescents. In Crecere Nel Mondo (eds Satorio, A. et al.) (Ferring Publisher, 2008)."},{"key":"51394_CR14","volume-title":"Human Biology: Guide to Field Methods","author":"J Hiernaux","year":"1969","unstructured":"Hiernaux, J. & Tanner, J. M. Growth and physical studies. In Human Biology: Guide to Field Methods (eds Weiner, J. S. & Lourie, S. A.) (IBP, London, 1969)."},{"key":"51394_CR15","volume-title":"Clinical Guide to Laboratory Tests","author":"NW Tietz","year":"1995","unstructured":"Tietz, N. W. Clinical Guide to Laboratory Tests 3rd edn. (WB Saunders Co., 1995).","edition":"3"},{"issue":"11","key":"51394_CR16","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/clinchem\/30.11.1797","volume":"30","author":"PN Demacker","year":"1984","unstructured":"Demacker, P. N., Hijmans, A. G., Brenninkmeijer, B. J., Jansen, A. P. & van\u2019t Laar, A. Five methods for determining low-density lipoprotein cholesterol compared. Clin. Chem. 30(11), 1797\u20131800 (1984).","journal-title":"Clin. Chem."},{"issue":"3","key":"51394_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cellsig.2015.07.021","volume":"28","author":"MA Wasilewski","year":"2016","unstructured":"Wasilewski, M. A., Myers, V. D., Recchia, F. A., Feldman, A. M. & Tilley, D. G. Arginine vasopressin receptor signaling and functional outcomes in heart failure. Cell. Signal. 28(3), 224\u2013233 (2016).","journal-title":"Cell. Signal."},{"issue":"8","key":"51394_CR18","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.euroneuro.2018.05.015","volume":"28","author":"G Li","year":"2018","unstructured":"Li, G. et al. Role of adipokines FGF21, leptin and adiponectin in self-concept of youths with obesity. Eur. Neuropsychopharmacol. 28(8), 892\u2013902 (2018).","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"51394_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.numecd.2021.09.025","volume":"32","author":"M Martin","year":"2022","unstructured":"Martin, M. et al. Vascular inflammation and impaired reverse cholesterol transport and lipid metabolism in obese children and adolescents. Nutr. Metab. Cardiovasc. Dis. 32(1), 258\u2013268 (2022).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"1","key":"51394_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43054-019-0012-8","volume":"68","author":"NS Mohamed","year":"2020","unstructured":"Mohamed, N. S., Maher, S. E., Abozaid, S. M. & Moenes, H. M. Anthropometric and metabolic pattern in obese Egyptian children: Its association with C-reactive protein. Egypt. Pediatr. Assoc. Gaz. 68(1), 1\u20136 (2020).","journal-title":"Egypt. Pediatr. Assoc. Gaz."},{"issue":"4","key":"51394_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/nu5041218","volume":"5","author":"B Klop","year":"2013","unstructured":"Klop, B., Elte, J. W. & Cabezas, M. C. Dyslipidemia in obesity: Mechanisms and potential targets. Nutrients 5(4), 1218\u20131240 (2013).","journal-title":"Nutrients"},{"issue":"6","key":"51394_CR22","first-page":"821","volume":"9","author":"EV Christaki","year":"2022","unstructured":"Christaki, E. V. et al. Circulating FGF21 vs. stress markers in girls during childhood and adolescence, and in their caregivers: Intriguing inter-relations between overweight\/obesity, emotions, behavior, and the cared-caregiver relationship. Children (Basel) 9(6), 821 (2022).","journal-title":"Children (Basel)"},{"issue":"8","key":"51394_CR23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/MEG.0000000000001608","volume":"32","author":"ZA Elkabany","year":"2020","unstructured":"Elkabany, Z. A. et al. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: Relation to transient elastography with controlled attenuation parameter. Eur. J. Gastroenterol. Hepatol. 32(8), 1008\u20131016 (2020).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"51394_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s12020-021-02762-6","volume":"73","author":"A Serbis","year":"2021","unstructured":"Serbis, A., Giapros, V., Paschou, S. A. & Siomou, E. Children with metabolically healthy obesity have a worse metabolic profile compared to normal-weight peers: A cross-sectional study. Endocrine 73(3), 580\u2013587 (2021).","journal-title":"Endocrine"},{"issue":"4","key":"51394_CR25","first-page":"245","volume":"21","author":"V Catal\u00e1n","year":"2011","unstructured":"Catal\u00e1n, V. et al. Association of increased visfatin\/PBEF\/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr. Metab. Cardiovasc. Dis. 21(4), 245\u2013253 (2011).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"4","key":"51394_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4274\/jcrpe.galenos.2022.2022-1-15","volume":"14","author":"F Akduman","year":"2022","unstructured":"Akduman, F. et al. FGF21 levels and bone mineral density in metabolically healthy and metabolically unhealthy obese children. J. Clin. Res. Perdiatr. Endocrinol. 14(4), 433\u2013443 (2022).","journal-title":"J. Clin. Res. Perdiatr. Endocrinol."},{"issue":"6","key":"51394_CR27","first-page":"2124","volume":"26","author":"K Ugur","year":"2022","unstructured":"Ugur, K. et al. Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome. Eur. Rev. Med. Pharmacol. Sci. 26(6), 2124\u20132133 (2022).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"51394_CR28","first-page":"169","volume":"61","author":"A Kami\u0144ska","year":"2010","unstructured":"Kami\u0144ska, A. et al. An evaluation of visfatin levels in obese subjects. Endokrynol. Polska 61(2), 169\u2013173 (2010).","journal-title":"Endokrynol. Polska"},{"issue":"2","key":"51394_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.2047-6310.2013.00149.x","volume":"9","author":"SQ Ooi","year":"2014","unstructured":"Ooi, S. Q. et al. Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children. Pediatr. Obes. 9(2), 81\u201391 (2014).","journal-title":"Pediatr. Obes."},{"issue":"3","key":"51394_CR30","first-page":"9","volume":"14","author":"SM Alnowihi","year":"2020","unstructured":"Alnowihi, S. M., Al Doghaither, H. A. & Osman, N. N. Serum visfatin concentration and its relationship with sex hormones in obese Saudi women. Int. J. Health Sci. 14(3), 9\u201313 (2020).","journal-title":"Int. J. Health Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51394-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T05:06:47Z","timestamp":1705036007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51394-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51394"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51394-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"8 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1190"}}